ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,665.29
      1.34%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aclaris Therapeutics Inc (ACRS)

      7. Aclaris Therapeutics Inc (ACRS) News

      ACRS

      Aclaris Therapeutics (ACRS)

      Aclaris Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ACRS
      DateTimeSourceHeadlineSymbolCompany
      10/17/20189:44PMGlobeNewswire Inc.Aclaris Announces Pricing of Public Offering of Common StockNASDAQ:ACRSAclaris Therapeutics Inc
      10/17/20184:05PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ACRSAclaris Therapeutics Inc
      10/17/20184:01PMGlobeNewswire Inc.Aclaris Announces Proposed Public Offering of Common StockNASDAQ:ACRSAclaris Therapeutics Inc
      10/15/20184:20PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACRSAclaris Therapeutics Inc
      10/15/20184:01PMGlobeNewswire Inc.Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from AllerganNASDAQ:ACRSAclaris Therapeutics Inc
      10/05/20184:46PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACRSAclaris Therapeutics Inc
      10/04/20185:02PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACRSAclaris Therapeutics Inc
      10/03/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall...NASDAQ:ACRSAclaris Therapeutics Inc
      10/02/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ACRSAclaris Therapeutics Inc
      10/01/20184:01PMGlobeNewswire Inc.Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA® (hydrogen peroxide) Topical Solution 40%, (w/w)NASDAQ:ACRSAclaris Therapeutics Inc
      10/01/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Under...NASDAQ:ACRSAclaris Therapeutics Inc
      09/24/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common WartsNASDAQ:ACRSAclaris Therapeutics Inc
      09/21/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ACRSAclaris Therapeutics Inc
      09/17/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target MeetingNASDAQ:ACRSAclaris Therapeutics Inc
      09/11/20184:58PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ACRSAclaris Therapeutics Inc
      09/05/20184:01PMGlobeNewswire Inc.Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ACRSAclaris Therapeutics Inc
      09/04/20182:54PMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:ACRSAclaris Therapeutics Inc
      08/27/20184:48PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACRSAclaris Therapeutics Inc
      08/21/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer ResearchNASDAQ:ACRSAclaris Therapeutics Inc
      08/17/20184:57PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACRSAclaris Therapeutics Inc
      08/13/20182:26PMEdgar (US Regulatory)Amended Small Company Offering and Sale of Securities Without Registration (d/a)NASDAQ:ACRSAclaris Therapeutics Inc
      08/03/20188:20AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACRSAclaris Therapeutics Inc
      08/03/20187:16AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACRSAclaris Therapeutics Inc
      08/03/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Development...NASDAQ:ACRSAclaris Therapeutics Inc
      08/02/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ACRSAclaris Therapeutics Inc
      07/26/20187:00AMGlobeNewswire Inc.Aclaris Therapeutics to Announce Second Quarter 2018 Financial Results on August 3, 2018NASDAQ:ACRSAclaris Therapeutics Inc
      07/10/201810:54AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACRSAclaris Therapeutics Inc
      07/09/20187:00AMGlobeNewswire Inc.FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Area...NASDAQ:ACRSAclaris Therapeutics Inc
      07/03/20184:01PMGlobeNewswire Inc.Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ACRSAclaris Therapeutics Inc
      06/28/20184:30PMGlobeNewswire Inc.Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with...NASDAQ:ACRSAclaris Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ACRS